

Jolanda de Vries

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6536515/publications.pdf>

Version: 2024-02-01

226
papers

17,136
citations

13099

68
h-index

17105

122
g-index

232
all docs

232
docs citations

232
times ranked

19430
citing authors

#	ARTICLE	IF	CITATIONS
1	Dendritic cell immunotherapy: mapping the way. <i>Nature Medicine</i> , 2004, 10, 475-480.	30.7	896
2	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. <i>Nature Biotechnology</i> , 2005, 23, 1407-1413.	17.5	791
3	Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. <i>Nature Reviews Immunology</i> , 2007, 7, 790-802.	22.7	678
4	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. <i>Cancer Research</i> , 2003, 63, 12-7.	0.9	659
5	Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. <i>Clinical Cancer Research</i> , 2014, 20, 2831-2837.	7.0	349
6	Induction of complete and molecular remissions in acute myeloid leukemia by Wilms's tumor 1 antigen-targeted dendritic cell vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13824-13829.	7.1	341
7	The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for <i>Candida albicans</i> on dendritic cells. <i>European Journal of Immunology</i> , 2003, 33, 532-538.	2.9	336
8	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. <i>Cancer Research</i> , 2013, 73, 1063-1075.	0.9	295
9	Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. <i>Clinical Cancer Research</i> , 2016, 22, 1897-1906.	7.0	295
10	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 3100-3108.	8.2	271
11	Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. <i>Blood</i> , 2005, 106, 1278-1285.	1.4	265
12	¹⁹ F MRI for quantitative in vivo cell tracking. <i>Trends in Biotechnology</i> , 2010, 28, 363-370.	9.3	252
13	Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. <i>Acta Biomaterialia</i> , 2018, 73, 38-51.	8.3	236
14	Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. <i>Clinical Cancer Research</i> , 2003, 9, 5091-100.	7.0	235
15	Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN- γ production. <i>Blood</i> , 2008, 111, 4245-4253.	1.4	230
16	Migrating into the Tumor: a Roadmap for T Cells. <i>Trends in Cancer</i> , 2017, 3, 797-808.	7.4	230
17	Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1573-1582.	4.2	220
18	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. <i>Lancet Oncology</i> , 2012, 13, e32-e42.	10.7	219

#	ARTICLE	IF	CITATIONS
19	The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. <i>Blood</i> , 2012, 119, 2284-2292.	1.4	217
20	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 5067-5078.	7.0	212
21	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	7.0	211
22	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. <i>Neuro-Oncology</i> , 2009, 11, 394-402.	1.2	203
23	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. <i>Journal of Immunology</i> , 2018, 200, 347-354.	0.8	181
24	Prognostic significance and mechanism of Treg infiltration in human brain tumors. <i>Journal of Neuroimmunology</i> , 2010, 225, 195-199.	2.3	180
25	Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 5779-5787.	1.6	174
26	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 2531-2540.	7.0	172
27	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRC) ocular melanoma study. <i>Annals of Oncology</i> , 2019, 30, 1370-1380.	1.2	171
28	Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5725-5735.	7.0	158
29	Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. <i>Blood</i> , 2013, 121, 459-467.	1.4	154
30	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1589-1597.	4.2	141
31	Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 429-438.	2.4	140
32	Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCR α 1 β 2 Genes Into Primary Human T Lymphocytes. <i>Journal of Immunology</i> , 2003, 170, 2186-2194.	0.8	138
33	Migration of dendritic cell based cancer vaccines: in vivo veritas?. <i>Current Opinion in Immunology</i> , 2005, 17, 170-174.	5.5	135
34	Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1383-1390.	5.6	131
35	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination. <i>Cancer Research</i> , 2013, 73, 19-29.	0.9	131
36	Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 462-472.	5.6	131

#	ARTICLE	IF	CITATIONS
37	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
38	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. <i>Frontiers in Immunology</i> , 2014, 5, 165.	4.8	127
39	Imaging of cellular therapies. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 1080-1093.	13.7	126
40	Labeling cells for in vivo tracking using 19F MRI. <i>Biomaterials</i> , 2012, 33, 8830-8840.	11.4	126
41	DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. <i>Journal of Leukocyte Biology</i> , 2009, 85, 518-525.	3.3	125
42	Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. <i>European Journal of Immunology</i> , 1993, 23, 956-960.	2.9	123
43	Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. <i>Biomaterials</i> , 2010, 31, 7070-7077.	11.4	120
44	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. <i>International Journal of Cancer</i> , 2011, 129, 507-512.	5.1	120
45	Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. <i>Nature Communications</i> , 2018, 9, 3317.	12.8	116
46	Dendritic cell vaccines in melanoma: From promise to proof?. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 118-134.	4.4	113
47	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1835-1841.	1.6	112
48	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	4.8	107
49	Lactate dehydrogenase: a marker of diminished antitumor immunity. <i>Oncolmmunology</i> , 2020, 9, 1731942.	4.6	107
50	Vaccination of Patients With Metastatic Renal Cell Carcinoma With Autologous Dendritic Cells Pulsed With Autologous Tumor Antigens in Combination With Interleukin-2: A Phase 1 Study. <i>Journal of Immunotherapy</i> , 2002, 25, 500-508.	2.4	99
51	Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion. <i>Journal of Immunology</i> , 2013, 191, 5005-5012.	0.8	98
52	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 4332-4346.	0.9	93
53	Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake. <i>Journal of Experimental Medicine</i> , 2006, 203, 1629-1635.	8.5	92
54	Dendritic cell vaccination and immune monitoring. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1559-1568.	4.2	91

#	ARTICLE	IF	CITATIONS
55	The nature of activatory and tolerogenic dendritic cell-derived signal II. <i>Frontiers in Immunology</i> , 2013, 4, 53.	4.8	91
56	Toll-like receptor signalling on Tregs: to suppress or not to suppress?. <i>Immunology</i> , 2008, 124, 445-452.	4.4	87
57	Functional assessment of human dendritic cells labeled for in vivo 19F magnetic resonance imaging cell tracking. <i>Cytotherapy</i> , 2010, 12, 238-250.	0.7	87
58	Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. <i>Blood</i> , 2010, 116, 564-574.	1.4	86
59	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 5460-5470.	7.0	86
60	Human Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response. <i>Frontiers in Immunology</i> , 2018, 9, 2489.	4.8	86
61	Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. <i>Annals of Oncology</i> , 2006, 17, 974-980.	1.2	85
62	Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. <i>International Journal of Cancer</i> , 2006, 120, 978-984.	5.1	82
63	Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor. <i>Clinical Cancer Research</i> , 2005, 11, 1899-1909.	7.0	80
64	Human Plasmacytoid Dendritic Cells Phagocytose, Process, and Present Exogenous Particulate Antigen. <i>Journal of Immunology</i> , 2010, 184, 4276-4283.	0.8	80
65	Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. <i>Blood</i> , 2012, 120, 3936-3944.	1.4	80
66	Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. <i>International Journal of Cancer</i> , 2008, 123, 2354-2361.	5.1	76
67	Human CD1c ⁺ DCs are critical cellular mediators of immune responses induced by immunogenic cell death. <i>Onc Immunology</i> , 2016, 5, e1192739.	4.6	74
68	Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function. <i>Cell Reports</i> , 2016, 16, 2953-2966.	6.4	72
69	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
70	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 191.	4.8	71
71	Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. <i>International Journal of Cancer</i> , 2007, 120, 67-74.	5.1	70
72	Multimodal Imaging of Nanovaccine Carriers Targeted to Human Dendritic Cells. <i>Molecular Pharmaceutics</i> , 2011, 8, 520-531.	4.6	70

#	ARTICLE	IF	CITATIONS
73	Frequency of Circulating Tregs with Demethylated <i>FOXP3</i> Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. <i>Clinical Cancer Research</i> , 2011, 17, 841-848.	7.0	70
74	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 249-260.	4.2	68
75	Opportunities for immunotherapy in microsatellite instable colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1249-1259.	4.2	67
76	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1057673.	4.6	67
77	Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. <i>Anticancer Research</i> , 2010, 30, 5091-7.	1.1	67
78	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3- ³ -fluoro-3-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18396-18399.	7.1	65
79	DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. <i>European Journal of Immunology</i> , 2011, 41, 1014-1023.	2.9	63
80	Tumoricidal activity of human dendritic cells. <i>Trends in Immunology</i> , 2014, 35, 38-46.	6.8	62
81	A novel ¹⁹ F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. <i>International Journal of Cancer</i> , 2011, 129, 365-373.	5.1	61
82	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. <i>British Journal of Cancer</i> , 2010, 103, 1415-1421.	6.4	60
83	Maximizing dendritic cell migration in cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 865-874.	3.1	59
84	Targeting of ¹¹¹ In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1525-1533.	7.0	58
85	A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. <i>Mediators of Inflammation</i> , 2016, 2016, 1-11.	3.0	57
86	In situ Expression of Tumor Antigens by Messenger RNA-Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. <i>Cancer Research</i> , 2009, 69, 2927-2934.	0.9	56
87	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. <i>Oncolmmunology</i> , 2015, 4, e1019197.	4.6	55
88	Long-lasting multifunctional CD8 ⁺ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1067745.	4.6	55
89	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Oncolmmunology</i> , 2022, 11, .	4.6	54
90	Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. <i>Diabetologia</i> , 2012, 55, 1247-1257.	6.3	53

#	ARTICLE	IF	CITATIONS
91	Harnessing human plasmacytoid dendritic cells as professional APCs. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1279-1288.	4.2	53
92	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. <i>American Journal of Ophthalmology</i> , 2014, 158, 939-947.e5.	3.3	53
93	The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. <i>Nature Communications</i> , 2020, 11, 2749.	12.8	51
94	Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. <i>Annals of Oncology</i> , 2004, 15, iv145-iv151.	1.2	50
95	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma. <i>Cancer Research</i> , 2012, 72, 6102-6110.	0.9	50
96	Improving cancer immunotherapy by targeting the STATE of MDSCs. <i>Oncolimmunology</i> , 2016, 5, e1196312.	4.6	50
97	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 327-339.	4.2	50
98	Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4+ T lymphocytes. <i>International Journal of Cancer</i> , 2002, 100, 441-444.	5.1	49
99	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. <i>PLoS ONE</i> , 2012, 7, e51851.	2.5	48
100	Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1461-1473.	4.2	47
101	Multicore Liquid Perfluorocarbon-Loaded Multimodal Nanoparticles for Stable Ultrasound and ¹⁹ F MRI Applied to In Vivo Cell Tracking. <i>Advanced Functional Materials</i> , 2019, 29, 1806485.	14.9	47
102	Dominant Processes during Human Dendritic Cell Maturation Revealed by Integration of Proteome and Transcriptome at the Pathway Level. <i>Journal of Proteome Research</i> , 2010, 9, 1727-1737.	3.7	45
103	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. <i>Ophthalmology</i> , 2016, 123, 2265-2267.	5.2	44
104	Tracking Targeted Bimodal Nanovaccines: Immune Responses and Routing in Cells, Tissue, and Whole Organism. <i>Molecular Pharmaceutics</i> , 2014, 11, 4299-4313.	4.6	42
105	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
106	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1101-1111.	4.2	41
107	Subsets of CD1c+ DCs: Dendritic Cell Versus Monocyte Lineage. <i>Frontiers in Immunology</i> , 2020, 11, 559166.	4.8	41
108	Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination. <i>Critical Reviews in Immunology</i> , 2014, 34, 517-536.	0.5	40

#	ARTICLE	IF	CITATIONS
109	Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG. <i>Frontiers in Immunology</i> , 2018, 9, 1412.	4.8	40
110	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. <i>Cancer Letters</i> , 2017, 403, 159-164.	7.2	37
111	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 4390-4399.	7.0	36
112	PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by ¹⁹ F MRI. <i>Nanomedicine</i> , 2015, 10, 2339-2348.	3.3	34
113	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. <i>Cancer Research</i> , 2016, 76, 3496-3506.	0.9	33
114	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. <i>Translational Oncology</i> , 2019, 12, 361-367.	3.7	33
115	Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. <i>Journal of Cutaneous Pathology</i> , 2000, 27, 436-440.	1.3	32
116	STATing the importance of immune modulation by platinum chemotherapeutics. <i>Oncolmunology</i> , 2012, 1, 234-236.	4.6	31
117	Cell tracking using ¹⁹ F magnetic resonance imaging: Technical aspects and challenges towards clinical applications. <i>European Radiology</i> , 2015, 25, 726-735.	4.5	31
118	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. <i>Molecular Imaging and Biology</i> , 2018, 20, 696-704.	2.6	30
119	Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 145-151.	4.2	29
120	Clinically-Applicable Perfluorocarbon-Loaded Nanoparticles For <i>In vivo</i> Photoacoustic, ¹⁹ F Magnetic Resonance And Fluorescent Imaging. <i>Nanotheranostics</i> , 2018, 2, 258-268.	5.2	29
121	Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. <i>Frontiers in Immunology</i> , 2019, 10, 824.	4.8	29
122	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. <i>Cancers</i> , 2020, 12, 2692.	3.7	29
123	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. <i>Cytotherapy</i> , 2020, 22, 388-397.	0.7	29
124	Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. <i>Cell Reports</i> , 2020, 30, 1027-1038.e4.	6.4	29
125	Phenotypical and Functional Characterization of Clinical-Grade Dendritic Cells. , 2005, 109, 113-126.		28
126	Regulation of MYCN expression in human neuroblastoma cells. <i>BMC Cancer</i> , 2009, 9, 239.	2.6	28

#	ARTICLE	IF	CITATIONS
127	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. <i>Clinical Cancer Research</i> , 2011, 17, 4541-4549.	7.0	28
128	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. <i>Cancers</i> , 2021, 13, 2249.	3.7	28
129	Unraveling the human dendritic cell phagosome proteome by organellar enrichment ranking. <i>Journal of Proteomics</i> , 2012, 75, 1547-1562.	2.4	27
130	Naturally circulating dendritic cells to vaccinate cancer patients. <i>Oncolmmunology</i> , 2013, 2, e23431.	4.6	27
131	Engineering monocyte-derived dendritic cells to secrete interferon- γ enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 831-842.	4.2	27
132	Cancer vaccine triggers antiviral-type defences. <i>Nature</i> , 2016, 534, 329-331.	27.8	27
133	Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 631713.	4.8	27
134	Innate Lymphoid Cells in Tumor Immunity. <i>Biomedicines</i> , 2016, 4, 7.	3.2	26
135	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. <i>Journal of Immunotherapy</i> , 2016, 39, 241-248.	2.4	26
136	Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. <i>Oncolmmunology</i> , 2016, 5, e1227902.	4.6	26
137	A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. <i>Nature Communications</i> , 2022, 13, 2366.	12.8	26
138	Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1109-1115.	4.2	25
139	Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1030-1040.	2.9	25
140	Relevance of DC-SIGN in DC-induced T cell proliferation. <i>Journal of Leukocyte Biology</i> , 2007, 81, 729-740.	3.3	24
141	In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1667-1676.	4.2	24
142	Selective cancer-germline gene expression in pediatric brain tumors. <i>Journal of Neuro-Oncology</i> , 2008, 88, 273-280.	2.9	24
143	Activation of Human Plasmacytoid Dendritic Cells by TLR9 Impairs Fc γ RII-Mediated Uptake of Immune Complexes and Presentation by MHC Class II. <i>Journal of Immunology</i> , 2008, 181, 5219-5224.	0.8	24
144	Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. <i>Molecular Immunology</i> , 2011, 48, 810-817.	2.2	24

#	ARTICLE	IF	CITATIONS
145	Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2003-2011.	4.2	24
146	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952.	1.5	24
147	Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation. <i>Biomedicines</i> , 2015, 3, 282-303.	3.2	22
148	Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System. <i>International Journal of Molecular Sciences</i> , 2018, 19, 273.	4.1	22
149	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>Oncolimmunology</i> , 2020, 9, 1774298.	4.6	22
150	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. <i>Frontiers in Immunology</i> , 2021, 12, 768957.	4.8	22
151	Cross-Talk between Human Dendritic Cell Subsets Influences Expression of RNA Sensors and Inhibits Picornavirus Infection. <i>Journal of Innate Immunity</i> , 2010, 2, 360-370.	3.8	21
152	In vivo imaging of therapy-induced anti-cancer immune responses in humans. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2237-2257.	5.4	21
153	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolimmunology</i> , 2016, 5, e1201625.	4.6	21
154	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. <i>Frontiers in Immunology</i> , 2021, 12, 641703.	4.8	21
155	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
156	A large-scale ¹⁹ F MRI-based cell migration assay to optimize cell therapy. <i>NMR in Biomedicine</i> , 2012, 25, 1095-1103.	2.8	20
157	Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. <i>Oncolimmunology</i> , 2013, 2, e24661.	4.6	20
158	Dendritic Cells Require PINK1-Mediated Phosphorylation of BCKDE1 β to Promote Fatty Acid Oxidation for Immune Function. <i>Frontiers in Immunology</i> , 2019, 10, 2386.	4.8	20
159	Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy. <i>Oncotarget</i> , 2017, 8, 19879-19893.	1.8	20
160	IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1. <i>Journal of Investigative Dermatology</i> , 2011, 131, 900-906.	0.7	19
161	In Vivo Tracking Techniques for Cellular Regeneration, Replacement, and Redirection. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1825-1828.	5.0	19
162	Cell tracking using multimodal imaging. <i>Contrast Media and Molecular Imaging</i> , 2013, 8, 432-438.	0.8	19

#	ARTICLE	IF	CITATIONS
163	The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 724883.	4.8	19
164	In vivo&/em> <sup>19&/sup>F MRI for Cell Tracking. <i>Journal of Visualized Experiments</i> , 2013, , e50802.	0.3	18
165	Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites. <i>Frontiers in Immunology</i> , 2019, 9, 3156.	4.8	18
166	Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists. <i>European Journal of Immunology</i> , 2015, 45, 2798-2809.	2.9	17
167	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1191732.	4.6	17
168	Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. <i>Oncolmmunology</i> , 2021, 10, 1935557.	4.6	17
169	Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. <i>Scientific Reports</i> , 2017, 7, 43486.	3.3	16
170	The lymphoid chemokine CCL21 triggers LFA-1 adhesive properties on human dendritic cells. <i>Immunology and Cell Biology</i> , 2011, 89, 458-465.	2.3	15
171	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	3.3	15
172	Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1425-1436.	4.2	15
173	Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. <i>Oncotarget</i> , 2017, 8, 67439-67456.	1.8	15
174	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
175	Development of ¹¹¹ In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. <i>Nuclear Medicine and Biology</i> , 2006, 33, 453-458.	0.6	14
176	Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. <i>Histopathology</i> , 2017, 70, 643-649.	2.9	14
177	Design of triphasic poly(lactic-co-glycolic acid) nanoparticles containing a perfluorocarbon phase for biomedical applications. <i>RSC Advances</i> , 2018, 8, 6460-6470.	3.6	14
178	Immunological responses to adjuvant vaccination with combined CD1c ⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolmmunology</i> , 2022, 11, .	4.6	14
179	Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. <i>Immunobiology</i> , 2015, 220, 243-248.	1.9	13
180	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. <i>Familial Cancer</i> , 2016, 15, 289-296.	1.9	13

#	ARTICLE	IF	CITATIONS
181	BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?. <i>Vaccines</i> , 2018, 6, 65.	4.4	13
182	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>Oncolimmunology</i> , 2020, 9, 1738814.	4.6	13
183	Recent Advances and Future Perspective of DC-Based Therapy in NSCLC. <i>Frontiers in Immunology</i> , 2021, 12, 704776.	4.8	13
184	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. <i>Oncotarget</i> , 2017, 8, 54434-54443.	1.8	13
185	Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFN γ secretion. <i>Immunobiology</i> , 2012, 217, 1017-1024.	1.9	11
186	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. <i>Oncolimmunology</i> , 2013, 2, e24440.	4.6	11
187	Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report. <i>Frontiers in Oncology</i> , 2018, 8, 562.	2.8	11
188	STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics. <i>Journal of Immunology Research</i> , 2019, 2019, 1-12.	2.2	11
189	Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming. <i>European Journal of Immunology</i> , 2021, 51, 1494-1504.	2.9	11
190	Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2007, 49, 924-927.	1.5	10
191	Targets for active immunotherapy against pediatric solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 831-841.	4.2	10
192	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. <i>Journal of Translational Medicine</i> , 2016, 14, 88.	4.4	10
193	Eosinophils and Cytokines. , 1993, 43, 197-208.		10
194	Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. <i>BMC Immunology</i> , 2012, 13, 71.	2.2	9
195	Metabolomic and lipidomic signatures associated with activation of human cDC1 (BDCA3 ⁺ /CD141 ⁺) dendritic cells. <i>Immunology</i> , 2022, 165, 99-109.	4.4	8
196	Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion. , 2022, 10, e004309.		8
197	Potential applications for plasmacytoid dendritic cells in cancer immunotherapy. <i>Immunotherapy</i> , 2012, 4, 979-982.	2.0	7
198	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	2.4	7

#	ARTICLE	IF	CITATIONS
199	An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8 $\hat{+}$ Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. <i>Frontiers in Immunology</i> , 2013, 4, 270.	4.8	6
200	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
201	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	1.6	5
202	Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites. <i>Bio-protocol</i> , 2017, 7, e2219.	0.4	5
203	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 802877.	4.8	5
204	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	2.8	4
205	Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome. <i>Gynecologic Oncology</i> , 2021, 160, 450-456.	1.4	4
206	In Vivo PET Imaging of Monocytes Labeled with [89Zr]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models. <i>Cancers</i> , 2021, 13, 5069.	3.7	4
207	Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [18F]FLT PET imaging. <i>Oncolmmunology</i> , 2012, 1, 744-745.	4.6	3
208	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e27219.	4.6	3
209	Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial. <i>Cancer Investigation</i> , 2018, 36, 371-377.	1.3	3
210	LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma. <i>Immuno</i> , 2021, 1, 67-77.	1.5	3
211	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. <i>Cancers</i> , 2021, 13, 2345.	3.7	3
212	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	4.6	3
213	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1634-1640.	3.3	2
214	Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients. <i>Journal of Translational Medicine</i> , 2015, 13, P12.	4.4	2
215	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. <i>Cancers</i> , 2021, 13, 4660.	3.7	2
216	Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilms \hat{c} ™ Tumor Protein WT1: A Phase I/II Trial.. <i>Blood</i> , 2007, 110, 158-158.	1.4	2

#	ARTICLE	IF	CITATIONS
217	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5036-5036.	1.6	2
218	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 219-219.	1.6	2
219	Scientific contributions toward successful cancer immunotherapy in The Netherlands. Immunology Letters, 2014, 162, 121-126.	2.5	1
220	<sc>PD–1</sc> in gestational trophoblastic disease: an antibody evaluation. Acta Obstetrica Et Gynecologica Scandinavica, 0, , .	2.8	1
221	Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. Cancer Immunology, Immunotherapy, 0, , .	4.2	1
222	Potential applications of dendritic cells. ISBT Science Series, 2007, 2, 264-271.	1.1	0
223	Dendritic cell vaccination and immune monitoring. ISBT Science Series, 2009, 4, 18-23.	1.1	0
224	Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome.. Journal of Clinical Oncology, 2012, 30, 9070-9070.	1.6	0
225	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
226	Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.		0